Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

Upcoming event - not listed/not published -
May 4-5, 2015

Tuesday - May 5
9:30 Selective Modulation of Fc Receptors for Improved Therapy of Orphan Autoimmune Diseases: Lessons from IVIg

Unpublished Data
Tony Manning, Ph.D., Vice President, Research, Momenta Pharmaceuticals

Based on extensive characterization of the mechanism of action of IVIg, both in animal models and in humans, we rationally designed a series of recombinant drug candidates with the potential to deliver improved therapeutic benefit compared to IVIg. These agents are termed Selective Immunodulators of Fc Receptors (SIF’s), and they selectively modulate the activity of members of the Fcg receptor family. In cell and animal models of immune-complex-mediated autoimmunity, SIF’s display up to 500-fold greater potency than IVIg.

http://www.pegsummit.com/Biologics-for-Autoimmune/

Tony Manning, Ph.D., Vice President, Research, Momenta Pharmaceuticals

A biomedical scientist by training, Tony has devoted the last 20 years to discovering novel therapeutics for autoimmune diseases.

He has been responsible for both the discovery of novel therapeutic targets and the advancement of large portfolios of both biologics and small molecules through pre-clinical and clinical development. Scientists under his leadership discovered the key components of the NF-?B signal transduction pathway, the I?B kinases and ligases, and have delivered multiple novel biologics and small molecules into clinical development. He contributed to the registration of Actemra and Rituxan for the treatment of rheumatoid arthritis. He has experience as a senior leader in both the global pharmaceutical and biotechnology industries, including Roche, Pharmacia, Biogen Idec, and Signal Pharmaceuticals (now Celgene). He has experience in guiding external collaborations, venture investments, and incubator companies, and served as a Board Observer for several biotechnology companies. Currently, he serves as Vice President of Research for Momenta Pharmaceuticals, a publically traded developer of complex generics, biosimilars and novel drugs. He is an author of over 100 publications and patents.

http://www.massbio.org/events/calendar/2916-part_iii_the_value_of_innovation_at_the/event_detail